186 related articles for article (PubMed ID: 11927223)
41. Valaciclovir to prevent Cytomegalovirus mediated adverse modulation of the immune system in ANCA-associated vasculitis (CANVAS): study protocol for a randomised controlled trial.
Chanouzas D; Dyall L; Nightingale P; Ferro C; Moss P; Morgan MD; Harper L
Trials; 2016 Jul; 17(1):338. PubMed ID: 27450392
[TBL] [Abstract][Full Text] [Related]
42. Effect of Pritelivir Compared With Valacyclovir on Genital HSV-2 Shedding in Patients With Frequent Recurrences: A Randomized Clinical Trial.
Wald A; Timmler B; Magaret A; Warren T; Tyring S; Johnston C; Fife K; Selke S; Huang ML; Stobernack HP; Zimmermann H; Corey L; Birkmann A; Ruebsamen-Schaeff H
JAMA; 2016 Dec; 316(23):2495-2503. PubMed ID: 27997653
[TBL] [Abstract][Full Text] [Related]
43. Quantitative effects of valacyclovir on the replication of cytomegalovirus (CMV) in persons with advanced human immunodeficiency virus disease: baseline CMV load dictates time to disease and survival. The AIDS Clinical Trials Group 204/Glaxo Wellcome 123-014 International CMV Prophylaxis Study Group.
Emery VC; Sabin C; Feinberg JE; Grywacz M; Knight S; Griffiths PD
J Infect Dis; 1999 Sep; 180(3):695-701. PubMed ID: 10438356
[TBL] [Abstract][Full Text] [Related]
44. The renal safety of high doses of valacyclovir for prevention of cytomegalovirus infection after renal transplantation.
Le Meur Y; Mons S; Moesch C; Leroux-Robert C
Nephrol Dial Transplant; 2000 Mar; 15(3):442. PubMed ID: 10692544
[No Abstract] [Full Text] [Related]
45. Valacyclovir versus acyclovir for HSV prophylaxisin neutropenic patients.
Warkentin DI; Epstein JB; Campbell LM; Yip JG; Cox VC; Ransier A; Barnett MJ; Marra F
Ann Pharmacother; 2002 Oct; 36(10):1525-31. PubMed ID: 12243600
[TBL] [Abstract][Full Text] [Related]
46. Efficacy and safety of maribavir dosed at 100 mg orally twice daily for the prevention of cytomegalovirus disease in liver transplant recipients: a randomized, double-blind, multicenter controlled trial.
Winston DJ; Saliba F; Blumberg E; Abouljoud M; Garcia-Diaz JB; Goss JA; Clough L; Avery R; Limaye AP; Ericzon BG; Navasa M; Troisi RI; Chen H; Villano SA; Uknis ME;
Am J Transplant; 2012 Nov; 12(11):3021-30. PubMed ID: 22947426
[TBL] [Abstract][Full Text] [Related]
47. Six months anti-viral prophylaxis significantly decreased cytomegalovirus disease compared with no anti-viral prophylaxis following renal transplantation.
Leone F; Akl A; Giral M; Dantal J; Blancho G; Soulillou JP; Cantarovich D
Transpl Int; 2010 Sep; 23(9):897-906. PubMed ID: 20230540
[TBL] [Abstract][Full Text] [Related]
48. A prospective randomized study of acyclovir versus ganciclovir plus human immune globulin prophylaxis of cytomegalovirus infection after solid organ transplantation.
Dunn DL; Gillingham KJ; Kramer MA; Schmidt WJ; Erice A; Balfour HH; Gores PF; Gruessner RW; Matas AJ; Payne WD
Transplantation; 1994 Mar; 57(6):876-84. PubMed ID: 8154035
[TBL] [Abstract][Full Text] [Related]
49. Prophylaxis of cytomegalovirus infection in renal transplantation.
Ostermann M; MacPhee I; Chang R
Nephrol Dial Transplant; 2001 Nov; 16(11):2276-9. PubMed ID: 11682689
[No Abstract] [Full Text] [Related]
50. High dose valacyclovir for cytomegalovirus prophylaxis following allogeneic hematopoietic cell transplantation.
Hawks KG; Fegley A; Sabo RT; Roberts CH; Toor AA
J Oncol Pharm Pract; 2023 Jan; 29(1):130-137. PubMed ID: 34854771
[TBL] [Abstract][Full Text] [Related]
51. The effect of daily valacyclovir suppression on herpes simplex virus type 2 viral shedding in HSV-2 seropositive subjects without a history of genital herpes.
Sperling RS; Fife KH; Warren TJ; Dix LP; Brennan CA
Sex Transm Dis; 2008 Mar; 35(3):286-90. PubMed ID: 18157071
[TBL] [Abstract][Full Text] [Related]
52. Valomaciclovir versus valacyclovir for the treatment of acute herpes zoster in immunocompetent adults: a randomized, double-blind, active-controlled trial.
Tyring SK; Plunkett S; Scribner AR; Broker RE; Herrod JN; Handke LT; Wise JM; Martin PA;
J Med Virol; 2012 Aug; 84(8):1224-32. PubMed ID: 22711350
[TBL] [Abstract][Full Text] [Related]
53. Prevention of primary cytomegalovirus disease in organ transplant recipients with oral ganciclovir or oral acyclovir prophylaxis.
Rubin RH; Kemmerly SA; Conti D; Doran M; Murray BM; Neylan JF; Pappas C; Pitts D; Avery R; Pavlakis M; Del Busto R; DeNofrio D; Blumberg EA; Schoenfeld DA; Donohue T; Fisher SA; Fishman JA
Transpl Infect Dis; 2000 Sep; 2(3):112-7. PubMed ID: 11429021
[TBL] [Abstract][Full Text] [Related]
54. Cytomegalovirus (CMV) prophylaxis by acyclovir in pre-transplant CMV-positive renal transplant recipients.
Rostaing L; Crespin A; Icart J; Lloveras JJ; Durand D; Martinet O; Didier J
Transpl Int; 1994; 7 Suppl 1():S331-5. PubMed ID: 11271244
[TBL] [Abstract][Full Text] [Related]
55. Valacyclovir for prevention of recurrent herpes labialis: 2 double-blind, placebo-controlled studies.
Baker D; Eisen D
Cutis; 2003 Mar; 71(3):239-42. PubMed ID: 12661753
[TBL] [Abstract][Full Text] [Related]
56. Pre-transplant ganciclovir and post transplant high-dose valacyclovir reduce CMV infections after alemtuzumab-based conditioning.
Kline J; Pollyea DA; Stock W; Artz A; Rich E; Godley L; Zimmerman T; Thompson K; Pursell K; Larson RA; van Besien K
Bone Marrow Transplant; 2006 Feb; 37(3):307-10. PubMed ID: 16400339
[TBL] [Abstract][Full Text] [Related]
57. Single-day, patient-initiated famciclovir therapy versus 3-day valacyclovir regimen for recurrent genital herpes: a randomized, double-blind, comparative trial.
Abudalu M; Tyring S; Koltun W; Bodsworth N; Hamed K
Clin Infect Dis; 2008 Sep; 47(5):651-8. PubMed ID: 18637755
[TBL] [Abstract][Full Text] [Related]
58. Less renal allograft fibrosis with valganciclovir prophylaxis for cytomegalovirus compared to high-dose valacyclovir: a parallel group, open-label, randomized controlled trial.
Reischig T; Kacer M; Hruba P; Hermanova H; Hes O; Lysak D; Kormunda S; Bouda M
BMC Infect Dis; 2018 Nov; 18(1):573. PubMed ID: 30442095
[TBL] [Abstract][Full Text] [Related]
59. Valganciclovir prophylaxis against cytomegalovirus impairs lymphocyte proliferation and activation in renal transplant recipients.
Reischig T; Prucha M; Sedlackova L; Lysak D; Jindra P; Bouda M; Matejovic M
Antivir Ther; 2011; 16(8):1227-35. PubMed ID: 22155904
[TBL] [Abstract][Full Text] [Related]
60. Beta-herpesvirus challenges in the transplant recipient.
Ljungman P
J Infect Dis; 2002 Oct; 186 Suppl 1():S99-S109. PubMed ID: 12353194
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
